SIGA Technologies shares rise 10% on approval of first-ever smallpox therapy

Discussion in 'Market News' started by sniper-academy, Jul 14, 2018 at 3:46 AM.


Draft saved Draft deleted
  1. sniper-academy

    sniper-academy Administrator Staff Member

    Joined:
    Sep 30, 2011
    Messages:
    251,289
    Likes Received:
    5
    SIGA Technologies Inc. rose 9.6% in Friday afternoon trade on the Food and Drug Administration's approval of its TPOXX, the first-ever smallpox therapy. The contagious and often-deadly disease -- described as "one of the world's most devastating diseases known to humanity" by the World Health Organization -- has been considered eradicated since 1980 due to global immunization, but there have been fears that it could be used for bioterrorism, the FDA said. TPOXX was the first drug to receive a "Material Threat Medical Countermeasure priority review voucher," which comes with various incentives for the drugmaker; the drug also received other special designations intended to encourage development of important drugs. To establish the product's safety, it was tested in 359 healthy humans who did not have smallpox, while the efficacy findings that the approval was based on were in animals. These types of approvals are allowed under the FDA's Animal Rule, used in cases when "it is not feasible or ethical to conduct efficacy trials in humans," the FDA said. SIGA shares have surged 9.1% over the last three months, compared with a 5.5% rise in the S&P 500 and a 2.7% rise in the Dow Jones Industrial Average .

    Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

    [​IMG]
    [​IMG] [​IMG] [​IMG] [​IMG]

    Continue reading...
     
Loading...

Share This Page